Physician profile
David Chaar
NPI 1417454356
$3,328.20
in general payments reported to CMS, 2019-2025
33 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2022: $233 · 2023: $501 · 2024: $787 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.72 |
| Education | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $428.91 | 2023-2025 | Briviact, Zilbrysq, Rystiggo |
| Pfizer INC. | $269.10 | 2023-2025 | |
| Abbvie INC. | $235.24 | 2023-2025 | Botox |
| Lilly USA, LLC | $231.26 | 2020-2025 | Kisunla, Amyvid |
| Janssen Biotech, INC. | $185.53 | 2025 | |
| Lundbeck LLC | $152.40 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $151.19 | 2022-2025 | Austedo Xr |
| Biogen, INC. | $149.99 | 2023-2024 | Tysabri, Skyclarys |
| Sk Life Science, INC. | $143.08 | 2023-2025 | |
| Kyowa Kirin, INC. | $135.58 | 2022-2024 | Nourianz |
| Argenx US, INC. | $134.99 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $123.86 | 2025 | Uplizna |
| Emd Serono, INC. | $107.10 | 2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $96.85 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $92.53 | 2023-2025 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $79.02 | 2024-2025 | Crexont |
| Acadia Pharmaceuticals INC | $68.98 | 2025 | Nuplazid, Daybue |
| Axsome Therapeutics, INC. | $56.64 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $54.50 | 2024 | Aptiom |
| Eisai INC. | $50.08 | 2024-2025 | |
| Abbott Laboratories | $45.04 | 2024-2025 | Proclaim, Infinity |
| Tanabe Pharma America, INC. | $42.11 | 2025 | Radicava |
| Jazz Pharmaceuticals INC. | $38.13 | 2025 | |
| Merz Pharmaceuticals, LLC | $37.54 | 2025 | Inbrija |
| Neurocrine Biosciences, INC. | $34.73 | 2023-2025 | Ingrezza |
| Biotronik Nro, INC. | $31.96 | 2024 | Prospera |
| Alnylam Pharmaceuticals INC. | $30.56 | 2025 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $26.90 | 2024 | Dysport |
| Genentech USA, INC. | $23.79 | 2025 | Ocrevus Zunovo |
| Livanova USA, INC. | $18.99 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals Lp | $18.60 | 2025 | |
| Cycle Pharmaceuticals INC | $17.12 | 2025 | Tascenso Odt |
| Sarepta Therapeutics, INC. | $15.90 | 2024 | Amondys 45 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.